163 related articles for article (PubMed ID: 34575390)
1. Early Improvements in Disease Activity Indices Predict Long-Term Clinical Remission Suggested by the Treat-to-Target Strategy in Patients with Ankylosing Spondylitis Receiving TNF-α Inhibitor Treatment.
Nam EJ; Lee WK
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575390
[TBL] [Abstract][Full Text] [Related]
2. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
[TBL] [Abstract][Full Text] [Related]
3. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
[TBL] [Abstract][Full Text] [Related]
4. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
[TBL] [Abstract][Full Text] [Related]
5. The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry.
Kim J; Kim MJ; Oh GY; Lee SK; Kim T; Shin K
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201714. PubMed ID: 37822329
[TBL] [Abstract][Full Text] [Related]
6. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.
Michielsens C; Bolhuis TE; van Gaalen FA; van den Hoogen F; Verhoef LM; den Broeder N; den Broeder AA
Scand J Rheumatol; 2024 May; 53(3):180-187. PubMed ID: 37339375
[TBL] [Abstract][Full Text] [Related]
7. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy.
Vastesaeger N; Cruyssen BV; Mulero J; Gratacós Masmitjá J; Zarco P; Almodovar R; Font P; Juanola X; Collantes-Estevez E;
Reumatol Clin; 2014; 10(4):204-9. PubMed ID: 24598027
[TBL] [Abstract][Full Text] [Related]
8. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
[TBL] [Abstract][Full Text] [Related]
9. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
Baraliakos X; Van den Bosch F; Machado PM; Gensler LS; Marzo-Ortega H; Sherif B; Quebe-Fehling E; Porter B; Gaillez C; Deodhar A
Rheumatol Ther; 2021 Mar; 8(1):273-288. PubMed ID: 33351179
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients.
Godfrin-Valnet M; Prati C; Puyraveau M; Toussirot E; Letho-Gyselink H; Wendling D
Joint Bone Spine; 2013 Jul; 80(4):393-8. PubMed ID: 23453478
[TBL] [Abstract][Full Text] [Related]
11. Disease activity assessment in ankylosing spondylitis in a Chinese cohort: BASDAI or ASDAS?
Au YL; Wong WS; Mok MY; Chung HY; Chan E; Lau CS
Clin Rheumatol; 2014 Aug; 33(8):1127-34. PubMed ID: 24981160
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.
Monti S; Todoerti M; Codullo V; Favalli EG; Biggioggero M; Becciolini A; Montecucco C; Caporali R
Mod Rheumatol; 2018 May; 28(3):542-549. PubMed ID: 28880727
[TBL] [Abstract][Full Text] [Related]
13. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
14. Equivalent cut-off values of Bath Ankylosing Spondylitis Disease Activity Index corresponding to Ankylosing Spondylitis Disease Activity Score cut-off values.
Cui R; Du Y; Tian N; Jiang HL; Tao YL; Dai SM
Clin Exp Rheumatol; 2023 May; 41(5):1163-1169. PubMed ID: 36226617
[TBL] [Abstract][Full Text] [Related]
15. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.
Tužil J; Mlčoch T; Jirčíková J; Závada J; Nekvindová L; Svoboda M; Uher M; Křístková Z; Vencovský J; Pavelka K; Doležal T
Expert Opin Biol Ther; 2020 Feb; 20(2):183-192. PubMed ID: 31736377
[No Abstract] [Full Text] [Related]
16. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
[TBL] [Abstract][Full Text] [Related]
17. [Scoring of disease activity using BASDAI and ASDAS method in ankylosing spondylitis].
Bobek D; Zagar I; Kovač-Durmiš K; Perić P; Ćurković B; Babić-Naglić Ð
Reumatizam; 2012; 59(1):5-10. PubMed ID: 25486721
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors.
Shimabuco AY; Gonçalves CR; Moraes JCB; Waisberg MG; Ribeiro ACM; Sampaio-Barros PD; Goldenstein-Schainberg C; Bonfa E; Saad CGS
Adv Rheumatol; 2018 Dec; 58(1):40. PubMed ID: 30657103
[TBL] [Abstract][Full Text] [Related]
19. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
Kilic E; Kilic G; Akgul O; Ozgocmen S
Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis.
Kılıç G; Kılıç E; Nas K; Karkucak M; Çapkın E; Dağlı AZ; Çevik R; Özgöçmen S
Clin Rheumatol; 2015 Mar; 34(3):515-21. PubMed ID: 24985042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
